Clinical Trials Logo

Relapsed Follicular Lymphoma clinical trials

View clinical trials related to Relapsed Follicular Lymphoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05604417 Withdrawn - Clinical trials for Refractory Follicular Lymphoma

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Start date: January 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.